Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Ethylene Glycol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL233064 | 1.00 | TDP1 (0.35) | TDP1TSHRTHRBALDH1A1LMNA | |
| SCHEMBL135673 | 0.91 | — | — | |
| SCHEMBL27510446 | 0.88 | — | — | |
| Methyl Alcohol SCHEMBL28185907 | 0.88 | — | — | |
| 1,3-Propanediol SCHEMBL28176999 | 0.86 | TDP1 (0.33) | TDP1ALDH1A1 | |
| Ethylene Glycol SCHEMBL990664 | 0.83 | TGFBR1 (0.31) | — | |
| Ethylene Glycol SCHEMBL234238 | 0.83 | TGFBR1 (0.31) | — | |
| Phosphoric Acid SCHEMBL2891155 | 0.83 | PPARD (0.31) | — | |
| Ethylene Glycol SCHEMBL990688 | 0.83 | TGFBR1 (0.31) | — | |
| Ethylene Glycol SCHEMBL990707 | 0.83 | TGFBR1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2249872-B1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9314463-B2 | Oligomer-diarylpiperazine conjugates | NEKTAR THERAPEUTICS (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150335640-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | NEKTAR THERAPEUTICS | 2015-11-26 | — | — | US | disclosed |
| US-9061026-B2 | Oligomer-diarylpiperazine conjugates | NEKTAR THERAPEUTICS (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140155412-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-06-05 | — | — | US | disclosed |
| US-20120004242-A1 | Oligomer-Diarylpiperazine Conjugates | NEKTAR THERAPEUTICS (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2249872-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | Nektar Therapeutics (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009094209-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155412-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | BIRC5, MTX2, IAPP | TDP1 2044/4885TSHR 4052/4885THRB 4567/4885 |
| US-20120004242-A1 | Oligomer-Diarylpiperazine Conjugates | BIRC5, MTX2, IAPP | TDP1 2044/4885TSHR 4052/4885THRB 4567/4885 |
| US-20150335640-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | BIRC5, MTX2, IAPP | TDP1 2044/4885TSHR 4052/4885THRB 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.